Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance

被引：0
|
作者：
Inyoung Lee
Jeremy D. Jokinen
Stephanie Y. Crawford
Gregory S. Calip
Ryan D. Kilpatrick
Todd A. Lee
机构：
[1] University of Illinois at Chicago,Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy
[2] Bristol-Myers Squibb Company,Center for Pharmacoepidemiology and Pharmacoeconomics Research
[3] University of Illinois at Chicago,undefined
[4] Flatiron Health,undefined
[5] Inc.,undefined
[6] AbbVie Inc.,undefined
来源：
Therapeutic Innovation & Regulatory Science | 2021年 / 55卷
关键词：
vigiGrade; Patient support program; Weighting; Completeness; Pharmacovigilance; Well documented;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：142 / 151
页数：9
相关论文
共 50 条
  • [21] Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System
    Battini, Vera
    Carnovale, Carla
    Clementi, Emilio
    Sessa, Maurizio
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (11) : 1105 - 1112
  • [22] TNF ANTAGONIST DRUG SAFETY ASSESSMENT BY PHARMACOVIGILANCE SIGNALING AND POST-MARKETING ADVERSE EVENT REPORTS
    Cavaco, M.
    Araujo, F.
    Eurico Fonseca, J.
    Goncalves, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 784 - 785
  • [23] A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance
    Ganesh Kumar Vemula
    Pavan Badale
    Petros Mavrogenis
    Isabelle Lalande-Luesink
    Michal Borkowski
    David John Lewis
    Advances in Therapy, 2024, 41 : 82 - 91
  • [24] A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance
    Vemula, Ganesh Kumar
    Badale, Pavan
    Mavrogenis, Petros
    Lalande-Luesink, Isabelle
    Borkowski, Michal
    Lewis, David John
    ADVANCES IN THERAPY, 2024, 41 (01) : 82 - 91
  • [25] A research framework for pharmacovigilance in health social media: Identification and evaluation of patient adverse drug event reports
    Liu, Xiao
    Chen, Hsinchun
    JOURNAL OF BIOMEDICAL INFORMATICS, 2015, 58 : 268 - 279
  • [26] Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting
    van der Boom, Meiwen D. X.
    van Eekeren, Rike
    van Hunsel, Florence P. A. M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (07) : 783 - 794
  • [27] Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
    Jia, Peng
    Zhou, Yusen
    Gao, Yuan
    Wang, Shangyu
    Yin, Jiangliu
    Lian, Yixiang
    Lai, Quanyou
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [28] A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
    Keith B. Hoffman
    Mo Dimbil
    Nicholas P. Tatonetti
    Robert F. Kyle
    Drug Safety, 2016, 39 : 561 - 575
  • [29] Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor
    Ali, Ayad K.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 337 - 344
  • [30] A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports
    Hoffman, Keith B.
    Dimbil, Mo
    Tatonetti, Nicholas P.
    Kyle, Robert F.
    DRUG SAFETY, 2016, 39 (06) : 561 - 575
12345